Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032

Urology

Volumn 77, Issue 5, 2011, Pages 1172-1176

  Smith, David C ^{a,b,c,d,e,f,g,h}   Tangen, Cathy M ^{a,b,c,d,e,f,g,h}   Van Veldhuizen Jr , Peter J ^{a,b,c,d,e,f,g,h}   Harrer, Grant W ^{a,b,c,d,e,f,g,h}   Golshayan, Ali ^{a,b,c,d,e,f,g,h}   Mills, Glenn M ^{a,b,c,d,e,f,g,h}   Vogelzang, Nicholas J ^{a,b,c,d,e,f,g,h}   Thompson, Ian M ^{a,b,c,d,e,f,g,h}   Hussain, Maha H A ^{a,b,c,d,e,f,g,h}  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Southwest Oncology Group   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d Montana Cancer Consortium CCOP   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f LOUISIANA STATE UNIVERSITY   (United States)

^g Department of Hematology Oncology   (United States)

^h UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; ESTRAMUSTINE; ETOPOSIDE; FAMOTIDINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; WARFARIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ANDROGEN THERAPY; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; DRUG EFFICACY; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; IMPOTENCE; KIDNEY FAILURE; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROTHROMBIN TIME; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; ESTRAMUSTINE; ETOPOSIDE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79955613960     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.12.043     Document Type: Article

References (10)

1. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990. (Pubitemid 46630748)
2. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008;26:5936-5942.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520. (Pubitemid 39315318)
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;2351:1502-1512. (Pubitemid 39315317)
5. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14:1982-1992.
6. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17:3553-3559. (Pubitemid 29517927)
7. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360. (Pubitemid 38101630)
8. Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. [Erratum in J Clin Oncol 2009;27:3263]. J Clin Oncol. 2009;27:2122-2128.
9. Mackler NJ, Pienta KJ, Dunn RL, et al. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. Clin Genitourin Cancer. 2007;5:318-322. (Pubitemid 47271780)
10. Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol. 1999;17:1664-1671. (Pubitemid 29269234)